| Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 22519361 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
JIN Y., SUN W., GU D., YANG J., XU Z. & CHEN J. (2012) European Journal of Cancer Care Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis A number of studies have reported the difference between the 5-HT3 receptor antagonists and palonosetron in preventing the chemotherapy-induced nausea and vomiting (CINV). Through analysing the efficacy and safety in palonosetron-treated patients, it can provide evidence for palonosetron administration. We identified randomised controlled clinical trials comparing palonosetron with the first-generation 5-HT3 receptor antagonists in the prevention of CINV in cancer patients. Nine studies investigated the outcomes in a total of 3463 cases. Compared with the first-generation 5-HT3 receptor antagonists, the cumulative incidences of emesis were significantly reduced in the patients treated with palonosetron (0.25 mg i.v.) on the first day [relative risk (RR) = 1.11, 95% confidence interval (CI): 1.05-1.17], from 2 to 5 days (RR = 1.26, 95% CI: 1.16-1.36) and the overall five days (RR = 1.23, 95% CI: 1.13-1.34). Regarding the drug safety, there was no significant difference between palonosetron-treated group and the first-generation 5-HT3 receptor antagonists-treated group. Results from the analysis suggest that palonosetron is highly effective in preventing nausea and vomiting in the days after administration of moderately or highly emetogenic chemotherapy agents. |
| | |
Authors:
|
Y Jin; W Sun; D Gu; J Yang; Z Xu; J Chen |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-22 |
Journal Detail:
|
Title: European journal of cancer care Volume: - ISSN: 1365-2354 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9301979 Medline TA: Eur J Cancer Care (Engl) Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2012 Blackwell Publishing Ltd. |
Affiliation:
|
Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, and Department of Oncology, Huaian No. 1 Hospital Affiliated to Nanjing Medical University, Huaian, Jiangsu Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast ...
Next Document: Immunonutrition: Does It Have a Role in Improving Recovery in Patients Receiving a Stem Cell Transpl...